Recent Research Analysts’ Ratings Updates for 89bio (ETNB)

A number of firms have modified their ratings and price targets on shares of 89bio (NASDAQ: ETNB) recently:

• 3/22/2025 – 89bio had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 3/14/2025 – 89bio is now covered by analysts at The Goldman Sachs Group, Inc.. They set a “neutral” rating and a $11.00 price target on the stock.
• 3/13/2025 – 89bio is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $25.00 price target on the stock.
• 3/7/2025 – 89bio had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 2/28/2025 – 89bio had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock, down previously from $29.00.
• 2/19/2025 – 89bio had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 2/4/2025 – 89bio is now covered by analysts at Wolfe Research. They set an “outperform” rating on the stock.
• 2/1/2025 – 89bio had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 1/31/2025 – 89bio had its price target raised by analysts at UBS Group AG from $25.00 to $38.00. They now have a “buy” rating on the stock.

89bio Price Performance

89bio stock opened at $8.52 on Monday. The business has a fifty day moving average price of $8.94 and a 200-day moving average price of $8.42. The firm has a market capitalization of $1.24 billion, a P/E ratio of -2.93 and a beta of 1.17. The company has a debt-to-equity ratio of 0.09, a current ratio of 11.66 and a quick ratio of 11.66. 89bio, Inc. has a one year low of $5.99 and a one year high of $11.84.

89bio (NASDAQ:ETNB) last released its quarterly earnings results on Thursday, March 6th. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.42). As a group, equities research analysts forecast that 89bio, Inc. will post -3.19 EPS for the current year.

Insider Activity

In other news, Director Charles Mcwherter bought 5,000 shares of the business’s stock in a transaction on Tuesday, January 21st. The stock was acquired at an average price of $6.55 per share, with a total value of $32,750.00. Following the completion of the purchase, the director now directly owns 15,000 shares in the company, valued at $98,250. This represents a 50.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Ra Capital Management, L.P. purchased 5,714,285 shares of the firm’s stock in a transaction on Thursday, January 30th. The shares were acquired at an average cost of $8.75 per share, for a total transaction of $49,999,993.75. Following the completion of the purchase, the director now directly owns 19,554,319 shares of the company’s stock, valued at approximately $171,100,291.25. This represents a 41.29 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 2.80% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ETNB. Federated Hermes Inc. boosted its stake in shares of 89bio by 206.9% during the fourth quarter. Federated Hermes Inc. now owns 6,283 shares of the company’s stock valued at $49,000 after purchasing an additional 4,236 shares during the period. Quarry LP bought a new stake in 89bio during the 4th quarter valued at $55,000. Kingswood Wealth Advisors LLC purchased a new stake in 89bio during the 4th quarter valued at $86,000. Sandia Investment Management LP grew its holdings in 89bio by 28.5% in the 4th quarter. Sandia Investment Management LP now owns 11,286 shares of the company’s stock worth $88,000 after acquiring an additional 2,500 shares during the last quarter. Finally, Hsbc Holdings PLC purchased a new position in shares of 89bio in the fourth quarter valued at about $87,000.

89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.